Sinaptica Completes Scientific Advisory Board with Final Expert Appointment as Company Advances to Pivotal Trial in Alzheimer's | Region
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 28, 2024--
Source: eagletribune.com
Cortexyme Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cortexyme Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cortexyme Inc Today - Breaking & Trending Today
Cortexyme (NASDAQ:CRTX) Share Price Passes Above 200 Day Moving Average of $1.14
Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.14 and traded as high as $1.39. Cortexyme shares last traded at $1.34, with a volume of 51,197 shares traded. Cortexyme Stock Performance […]
Source: modernreaders.com
Critical Contrast: Senti Biosciences (NASDAQ:SNTI) versus Quince Therapeutics (NASDAQ:QNCX)
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Insider & Institutional Ownership 39.6% of Quince […]
Source: etfdailynews.com
Cortexyme (NASDAQ:CRTX) Shares Cross Above 200-Day Moving Average of $1.18
Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.18 and traded as high as $1.20. Cortexyme shares last traded at $1.15, with a volume of 36,188 shares. Cortexyme Price Performance The company has a market […]
Source: defenseworld.net
Quince Therapeutics, Inc. (NASDAQ:QNCX) Director Buys $22,773.54 in Stock
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 22,327 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was bought at an average price of $1.02 per share, for a total transaction of $22,773.54. Following the completion of the purchase, the director now directly owns 2,302,291 […]
Source: wkrb13.com